Mediwhale, the AI-powered health diagnostics company, announced $12 million series A2 investments. This funding leverages the momentum of their technological advancements and rapid adoption of its innovative biomarker for preventing cardiovascular disease in general hospitals and clinics.

人工智能驱动的健康诊断公司Mediwhale宣布了1200万美元的A2系列投资。这笔资金利用了他们技术进步的势头，并迅速采用了其创新的生物标志物，用于在综合医院和诊所预防心血管疾病。

The financing round was led by Korea Development Bank (KDB), with participation from Woori Venture Partners, IMM Investment, Mirae Asset Securities, and other investors. This investment involves both the issuance of new shares and secondary sales.

融资回合由韩国开发银行（KDB）牵头，Woori Venture Partners、IMM Investment、Mirae Asset Securities和其他投资者参与。这项投资涉及新股发行和二次销售。

Mediwhale initially raised $2 million in Series Pre-A funding in 2021, followed by $9 million in Series A funding in 2023. The recent Series A2 investment of $12million further strengthens the company's growth trajectory.

Mediwhale最初在2021年的A系列前期融资中筹集了200万美元，随后在2023年的A系列融资中筹集了900万美元。最近A2系列投资1200万美元，进一步巩固了公司的增长轨迹。

Mediwhale is setting a new standard of care for the early prevention of cardiovascular disease using AI-powered retina scans. The company's flagship product, Reti-CVD, is an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using an eye scan. It is a simple, radiation-free test that provides highly accurate results equivalent to the coronary artery calcium score derived from a cardiac CT scan in predicting cardiovascular risk.

Mediwhale正在使用人工智能视网膜扫描为早期预防心血管疾病制定新的护理标准。。这是一种简单的无辐射测试，可以提供与心脏CT扫描得出的冠状动脉钙评分相当的高度准确的结果，以预测心血管风险。

Since June 2023, Reti-CVD has been approved for private reimbursement in Korea and has been utilized in over 7,200 cases across 57 medical institutions as of August 2024..

自2023年6月以来，Reti CVD已被批准在韩国进行私人报销，截至2024年8月，已在57家医疗机构的7200多例病例中使用。。

With this new capital, Mediwhale will continue to enhance AI algorithms, achieve U.S. FDA approval for Reti-CVD, expand its global footprint, and develop new products to predict chronic kidney disease risk.

有了这一新资本，Mediwhale将继续增强人工智能算法，获得美国FDA对Reti CVD的批准，扩大其全球足迹，并开发新产品来预测慢性肾病风险。

'Mediwhale is the first company in the world to develop and commercialize medical AI that can predict cardiovascular disease risk through a simple eye exam. The company demonstrates significant differentiation in both business performance and technological innovation. We have decided to invest actively, confident that Mediwhale will make history in AI-driven prediction of cardiovascular and metabolic diseases both domestically and globally,' said Korea Development Bank..

“Mediwhale是世界上第一家开发和商业化医学人工智能的公司，该人工智能可以通过简单的眼科检查来预测心血管疾病的风险。该公司在业务表现和技术创新方面表现出显着的差异。韩国开发银行表示：“我们决定积极投资，相信Mediwhale将在国内外人工智能驱动的心血管和代谢疾病预测方面创造历史。”。。

Kevin Choi, CEO of Mediwhale, added, 'I believe that our successful fundraising, even in a frozen capital market, is largely due to our excellent technology. With our pioneering technology, developed and commercialized as a world first, we aim to lead the global market in cardiovascular and metabolic disease management.

Mediwhale首席执行官凯文·崔（KevinChoi）补充道，“我认为，即使在冻结的资本市场上，我们成功的筹资也很大程度上归功于我们出色的技术。凭借我们作为世界第一家开发和商业化的领先技术，我们的目标是领导心血管和代谢疾病管理的全球市场。

We are determined to secure FDA De Novo approval by 2025, with plans to launch our product in the United States shortly thereafter. Additionally, to maintain a competitive edge, we will significantly enhance our AI performance and expand our product pipeline to include chronic kidney disease prediction.'.

我们决心在2025年之前获得FDA的从头批准，并计划不久后在美国推出我们的产品。此外，为了保持竞争优势，我们将大大提高人工智能的性能，并扩大产品线，以包括慢性肾脏疾病的预测。”。

About Mediwhale

关于Mediwhale

Mediwhale is the AI-powered health diagnostics company that uses non-invasive retina scans to help prevent heart and kidney diseases. Mediwhale's solution uses deep learning algorithms to detect future disease risks even before symptoms appear. Mediwhale has been dedicated to making preventative care more affordable, accessible, safe, and convenient since being founded in 2016 in South Korea..

Mediwhale是人工智能驱动的健康诊断公司，它使用非侵入性视网膜扫描来帮助预防心脏和肾脏疾病。。自2016年在韩国成立以来，Mediwhale一直致力于使预防保健更实惠，更容易获得，更安全，更方便。。

Source: prnewswire.com

来源：prnewswire.com